The Power of Collaboration                     in Drug Development                                            Universities...
About the Evolution Summit 2012  The      Pharma        Network         –  marcus evans Summits group                     ...
Upcoming SlideShare
Loading in …5
×

Evolution summit 2012 michel goldman news releaseThe Power of Collaboration in Drug Development: Interview with: Professor Michel Goldman

195
-1

Published on

The Power of Collaboration in Drug Development: Interview with: Professor Michel Goldman, Executive Director, Innovative Medicines Initiative (IMI), a speaker at the marcus evans Evolution Summit 2012, on how public-private partnerships can advance the field of drug development.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
195
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Evolution summit 2012 michel goldman news releaseThe Power of Collaboration in Drug Development: Interview with: Professor Michel Goldman

  1. 1. The Power of Collaboration in Drug Development Universities are having a hard time also make the dialogue easier and convincing large pharma companies to prevent some conflict of interest issues. take their research findings on board, and they may underestimate the efforts U n t i l r e c e nt l y , c o m pan i e s w e r e that remain to be made. On the negotiating agreements with universities pharmaceutical company side, there are and partners in a way that was very business and regulatory considerations unidirectional. Open innovation is more that are preventing potentially useful bidirectional, which means that partners com pon en ts from be i n g fur th er outside industry will also benefit from developed. the expertise of companies for their own purposes. PPPs can address many of the bottlenecks in clinical research and the Any final comments?Interview with: Professor Michel difficulties in translating basicGoldman, Executive Director, discoveries into pharmaceutical The experience gained from theInnovative Medicines Initiative products. Innovative Medicines Initiatives and(IMI) other public-private endeavours clearly What opportunities does the public- demonstrate that PPP can be private model present to instrumental to address the majorThe only way to address major public pharmaceutical companies? What public health needs that humanhealth needs is through public-private does collaboration help them mankind is facing. However, to take fullpartnerships (PPPs), according to achieve? advantage of PPPs, further changes inProfessor Michel Goldman, Executive mindsets and culture will be necessaryDirector, Innovative Medicines Initiative Companies are targeting similar disease to bridge the world of industry and(IMI). With the complex scientific, areas and producing similar products, academia and make collaborations asbusiness and regulatory hurdles facing and investing resources and gathering fruitful as possible.both the public and private sectors, only data that are not shared. The samePPPs can pool the knowledge and failures may have been repeated inexpertise required to move the field of several companies. Some companiesdrug development forward. have now realised the benefits of inter- company collaboration in pre -A speaker at the upcoming marcus competitive or non-competitiveevans Evolution Summit 2012, in research. Indeed, companies can Public-privateMunich, Germany, 14 - 16 October, compete in the marketplace but agreeProfessor Goldman turns the spotlighton PPPs and discusses why there is a to work together on a project to mutualise risks and investments. partnershipsneed to bridge the world of industry andacademia in clinical trials. However, even those collaborations may not provide them with the knowledge can addressHow can PPPs accelerate drug that academia could. many of thedevelopment and time to market? The value of collaboration in this field is in sharing clinical data from successes bottlenecks inPharmaceutical companies and and failures. Combining data fromacademia are facing a number ofhurdles along the value chain, from different clinical trials allows them to eliminate a number of pre-clinical clinical researchbasic discovery of a potential models. For rare diseases, it gives themtherapeutic target until the access to patient cohorts. If companiescommercialisation of the drug. approach regulators through PPPs, it will
  2. 2. About the Evolution Summit 2012 The Pharma Network – marcus evans Summits group This unique forum will take place at the Hotel Four Seasons Kempinkski, Munich, delivers peer-to-peer information Germany, 14 - 16 October 2012. Offering much more than any conference, seminar on strategic matters, professional or trade show, this exclusive meeting will bring together esteemed industry thought trends and breakthrough leaders and solution providers to a highly focused and interactive networking event. innovations. The Summit includes presentations on pharmaceutical innovation, maximising clinical resources and delivering medical value, and reshaping R&D strategies. www.evolution-summit.com Contact Please note that the Summit is a Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits closed business event and the Division number of participants strictly limited. Tel: + 357 22 849 313 Email: press@marcusevanscy.com For more information please send an email to info@marcusevanscy.com All rights reserved. The above content may be republished or reproduced. Kindly inform us by sending an email to press@marcusevanscy.comAbout marcus evans Summitsmarcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discussstrategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity toindividually tailor their schedules of keynote presentations, think tanks, seminars and one-to-one business meetings.For more information, please visit: www.marcusevans.comUpcoming EventsDiscovery Summit (Europe) - www.discovery-summit.comDiscovery Summit (North America) - www.thediscoverysummit.comEvolution Summit (North America) - www.evolutionsummit.com.comTo view the web version of this interview, please click here: www.evolution-summit.com/MichelGoldman

×